Industry
Biotechnology
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Loading...
Open
0.69
Mkt cap
27M
Volume
35K
High
0.70
P/E Ratio
-1.84
52-wk high
1.90
Low
0.67
Div yield
N/A
52-wk low
0.57
Portfolio Pulse from
November 14, 2024 | 4:00 pm
Portfolio Pulse from
November 11, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 10:45 am
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 11:36 am
Portfolio Pulse from Benzinga Insights
October 04, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 6:28 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 11:45 am
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 11:36 am
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 6:02 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.